ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,942.47
1.26%
Dow Jones
42,732.13
0.80%
US Dollar vs MXN
20.6314
0.01%
Brent Oil
76.495
0.00%
Bitcoin
97,957.78
-0.15%
Pepperstone
Advertisement
Registration Strip Icon for discussion Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. AMEX

  6. Hemispherx Biopharma Inc New (HEB) Cotización

Hemispherx Biopharma Inc New

Hemispherx Biopharma Inc New (HEB)

Hamilton Canadian Bank Equal Weight Index ETF
1.80
0.00
(0.00%)
Cerrado 04 Enero 3:00PM
Delayed by 15 minutes
0.00
0.00
(0.00%)
Fuera de horario: -
Delayed by 15 minutes

Herramientas de nivel profesional para inversores individuales.

Premium

Estadísticas y detalles clave

Último Precio
1.80
Postura de Compra
-
Postura de Venta
-
Volume Operado de la Acción
-
0.00 Rango del Día 0.00
0.00 Rango de 52 semanas 0.00
Capitalización de Mercado [m]
87.916M
Precio Anterior
1.80
Precio de Apertura
-
Hora
Última hora de negociación
Volumen financiero
-
Precio Promedio Ponderado
-
Volumen promedio (3 m)
-
Acciones en circulación
48,842,000
Rendimiento del Dividendo
-
Ratio Precio/Utilidad
-3.04
Beneficio por acción (BPA)
-0.59
turnover
202k
Beneficio neto
-28.96M

Acerca de Hemispherx Biopharma Inc New

Hemispherx Biopharma Inc is a US-based specialty pharmaceutical company. It is engaged in the clinical development of drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune-based disorders. The products of the firm are Alferon N Injection and the e... Hemispherx Biopharma Inc is a US-based specialty pharmaceutical company. It is engaged in the clinical development of drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune-based disorders. The products of the firm are Alferon N Injection and the experimental therapeutic Ampligen. Alferon N Injection is approved for a category of STD infection, and Ampligen represents a RNA being developed for viral diseases and disorders of the immune system. The sales revenue of the company is derived from the United States. Mostrar más

Sector
Biological Pds,ex Diagnstics
Industria
Biological Pds,ex Diagnstics
Sitio web
www.aimimmuno.com
Sede
Wilmington, Delaware, USA
Fundado
-

HEB Últimas noticias

Más noticias

Hemispherx Biopharma, Inc. Changes Name to AIM ImmunoTech Inc. Reflecting Ampligen’s® Immuno Modulation Progress in Ongoin...

OCALA, Fla., Aug. 23, 2019 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE American: HEB), an immuno-tech company focused on the research and development of immunological agents to treat...

23 Agosto 2019
GlobeNewswire Inc.

Hemispherx Issues 2019 Second Quarter Report Citing Strong Steady Progress in Cancer Clinical Trials

OCALA, Fla., Aug. 15, 2019 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE American: HEB), an immuno-pharma company focused on the research and development of therapeutics to treat multiple...

15 Agosto 2019
GlobeNewswire Inc.

Hemispherx Reports Positive Safety and Survival Data in Phase 1 Stage 4 Ovarian Cancer Clinical Study Using Ampligen®

OCALA, Fla., Aug. 08, 2019 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE American: HEB) announced today that the University of Pittsburgh Medical Center (UPMC) has issued a final report...

08 Agosto 2019
GlobeNewswire Inc.

Hemispherx Secures Corrections from Two Stock News Organizations Related to Their Inaccurate Reporting of an Equity Distribut...

OCALA, Fla., Aug. 02, 2019 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE American: HEB) recently demanded and received retractions and corrections in two cases of inaccurate reporting due to AI...

02 Agosto 2019
GlobeNewswire Inc.

Hemispherx Biopharma CFO Adam Pascale Announces Retirement

OCALA, Fla., June 28, 2019 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE American: HEB) announced today that Adam Pascale is retiring from the position of Chief Financial Officer after...

28 Junio 2019
GlobeNewswire Inc.

Hemispherx Biopharma Issues Clinical Update for Ampligen Immuno-oncology Program

OCALA, Fla., June 17, 2019 (GLOBE NEWSWIRE) -- Hemispherx Biopharma Inc. (NYSE American: HEB) issued its quarterly update on the progress of its ongoing clinical trials evaluating Ampligen’s...

17 Junio 2019
GlobeNewswire Inc.

Hemispherx Biopharma Announces First Patient Treated in Phase 2 Ovarian Cancer Clinical Trial Evaluating Ampligen in Combinat...

OCALA, Fla., June 12, 2019 (GLOBE NEWSWIRE) -- (NYSE American: HEB) — Hemispherx Biopharma Inc. announced today that the first patient has been treated in the Phase 2 recurrent ovarian cancer...

12 Junio 2019
GlobeNewswire Inc.

Hemispherx Biopharma Stockholders Approve Reverse Stock Split

OCALA, Fla., May 31, 2019 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE American: HEB), an immuno-pharma company focused on the research and development of therapeutics to treat multiple...

31 Mayo 2019
GlobeNewswire Inc.

Hemispherx Reports 2019 First Quarter Financial Results

OCALA Fla., May 16, 2019 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE American: HEB), an immuno-pharma company focused on the research and development of therapeutics to treat multiple...

16 Mayo 2019
GlobeNewswire Inc.

Opening of Prostate Cancer Study at Roswell Park Comprehensive Cancer Center Edges Closer for Hemispherx Biopharma

ORLANDO, FL, May 13, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Hemispherx Biopharma Inc., (NYSE American: HEB), an immuno-pharma company focused on the research and development of...

13 Mayo 2019
GlobeNewswire Inc.
Período †Variación(Ptos)Variación %AperturaPrecio MáximoPrecio MínimoAvg. Vol. diarioPrecio Promedio Ponderado
10000000CS
40000000CS
120000000CS
260000000CS
520000000CS
1560000000CS
2600000000CS

HEB - Preguntas Frecuentes

¿Cuál es el precio actual de las acciones de Hemispherx Biopharma?
El precio actual de las acciones de Hemispherx Biopharma es US$ 1.80
¿Cuántas acciones de Hemispherx Biopharma están en circulación?
Hemispherx Biopharma tiene 48,842,000 acciones en circulación
¿Cuál es la capitalización de mercado de Hemispherx Biopharma?
La capitalización de mercado de Hemispherx Biopharma es USD 87.92M
¿Cuál es el rango de negociación de 1 año para el precio de las acciones de Hemispherx Biopharma?
Hemispherx Biopharma ha negociado en un rango de US$ 0.00 a US$ 0.00 durante el último año
¿Cuál es el ratio PE (precio/beneficio) de Hemispherx Biopharma?
El ratio precio/beneficio de Hemispherx Biopharma es -3.04
¿Cuál es el ratio de efectivo a ventas de Hemispherx Biopharma?
El ratio de efectivo a ventas de Hemispherx Biopharma es 439.02
¿Cuál es la moneda de reporte de Hemispherx Biopharma?
Hemispherx Biopharma presenta sus resultados financieros en USD
¿Cuál es el último ingresos anual de Hemispherx Biopharma?
El último ingresos anual de Hemispherx Biopharma es USD 202k
¿Cuál es el último beneficio anual de Hemispherx Biopharma?
El último beneficio anual de Hemispherx Biopharma es USD -28.96M
¿Cuál es la dirección registrada de Hemispherx Biopharma?
La dirección registrada de Hemispherx Biopharma es 251 LITTLE FALLS DRIVE, NEW CASTLE, WILMINGTON, DELAWARE, 19808
¿Cuál es la dirección del sitio web de Hemispherx Biopharma?
La dirección del sitio web de Hemispherx Biopharma es www.aimimmuno.com
¿En qué sector industrial opera Hemispherx Biopharma?
Hemispherx Biopharma opera en el sector BIOLOGICAL PDS,EX DIAGNSTICS

Movimientos

Ver todo
  • Volumen
  • % Mayores Alzas
  • % Mayores Bajas
SímboloPrecioVol.
SCPXScorpius Holdings Inc
US$ 0.54
(56.39%)
92.65M
EVAVDirexion Daily Electric and Autonomous Vehicles Bull 2x Shr
US$ 31.47
(41.93%)
67.51k
YCBDcbdMD Inc
US$ 0.5664
(36.81%)
10.52M
SYNXSilynxcom Ltd
US$ 4.98
(27.12%)
768.02k
MSTUT Rex 2X Long MSTR Daily Target ETF
US$ 10.21
(25.43%)
48.74M
MSTZT Rex 2X Inverse MSTR Daily Target ETF
US$ 19.24
(-26.06%)
16.46M
ITPIT Tech Packaging Inc
US$ 0.5227
(-21.99%)
1.83M
ATCHAtlasClear Holdings Inc
US$ 8.11
(-19.30%)
246.19k
TSLZT Rex 2X Inverse Tesla Daily Target ETF
US$ 2.35
(-15.92%)
59.36M
BURUNuburu Inc
US$ 0.6771
(-15.36%)
2.27M
SCPXScorpius Holdings Inc
US$ 0.54
(56.39%)
92.65M
SOXLDirexion Daily Semiconductor Bull 3X Shares
US$ 29.82
(7.77%)
72.12M
SPXSDirexion Daily S&P 500 Bear 3X Shares New
US$ 6.10
(-3.63%)
60.33M
TSLZT Rex 2X Inverse Tesla Daily Target ETF
US$ 2.35
(-15.92%)
59.36M
MSTUT Rex 2X Long MSTR Daily Target ETF
US$ 10.21
(25.43%)
48.74M

HEB Discussion

Ver más
mick mick 4 años hace
Hemispherx Biopharma (HEB)
1.8 ? 0.0 (0.00%)
Volume: 0 @-
Bid Ask Day's Range
- - - - -
HEB Detailed Quote
👍️0
Richard2 Richard2 4 años hace
I liked the original name better lol. Still think this drug has great potential, but I’m disappointed there wasn’t any news from the Japan trials.
👍️0
mick mick 5 años hace
Hemispherx Biopharma (HEB) NOW AIM
👍️0
deniseann deniseann 5 años hace
Thank you Richard, I couldn't seem to find anything on the change...
👍️0
Richard2 Richard2 5 años hace
‘AIM’ is the new ticker.
👍️0
Richard2 Richard2 5 años hace
No, the company changed its name and ticker. There’s a new board.
👍️0
deniseann deniseann 5 años hace
Is this still a real stock..?
👍️0
lowfloatwayne lowfloatwayne 5 años hace
Buying all i can it may be a long haul there is probably a reason they taking shares instead of all their pay. Hopefully a buy out.
👍️0
Richard2 Richard2 5 años hace
This drug could be huge in the me/cfs community, I really thought it would’ve received approval here in the states.
👍️0
LW89 LW89 5 años hace
They need cash so they can hit their finish and fill due in October...and they need to poly-line recertified for that to happen. They are still planning to send product to Argentina (filed the paperwork) - so regardless of what they in their PRs...someone in management is still pursuing ME/CFS where they have approvals to build on.
👍️0
lowfloatwayne lowfloatwayne 5 años hace
Their voting now to raise the share count from 2018
👍️0
lowfloatwayne lowfloatwayne 5 años hace
Acusphere has twice as many shares moves ez this should rocket eiyh the right hedge or buy out merger
👍️0
cspratt15139 cspratt15139 5 años hace
this is just sad. pure sad
👍️0
lowfloatwayne lowfloatwayne 5 años hace
Ok their not adding shares could be a 2008 run cant tell whats bottom they bought in at 2.30? Legally
👍️0
cspratt15139 cspratt15139 5 años hace
they do this to themselves
👍️0
lowfloatwayne lowfloatwayne 5 años hace
So they rs to 2.2m shares then dilute 70m shares https://seekingalpha.com/article/893871-tracking-recent-buy-calls-and-investments-by-the-maxim-group
I hope the can run a pump and dump and clay can do a video.
👍️0
aristotelisonassis aristotelisonassis 5 años hace
strong buy here. Bottom bouncer.
👍️0
cspratt15139 cspratt15139 6 años hace
Hope everyone is enjoying there weekend. Stay safe and blessed!
👍️0
cspratt15139 cspratt15139 6 años hace
Ampligen is picking up steam
👍️0
bleu22 bleu22 6 años hace
Fully funded trial up to 45-people, low float, looking for large pharmaceutical partnership, and more news on the way... I’m in. GLTA
👍️0
cspratt15139 cspratt15139 6 años hace
Going higher
👍️0
420man 420man 6 años hace
LOL..Can't even wait a few days to reward their Tutes via PR! And that's even after crushing retail for months. They will continue dumping all the way down helping shorty... I need to start shorting these plays. So damn predictable.
👍️0
bleu22 bleu22 6 años hace
They don’t even have options laid out yet. WTF
👍️0
whytestocks whytestocks 6 años hace
News: $HEB Hemispherx Biopharma Announces First Patient Treated in Phase 2 Ovarian Cancer Clinical Trial Evaluating Ampligen in Combination with Pembrolizumab and Cisplatin

OCALA, Fla., June 12, 2019 (GLOBE NEWSWIRE) -- (NYSE American: HEB) — Hemispherx Biopharma Inc. announced today that the first patient has been treated in the Phase 2 recurrent ovarian cancer program at the University of Pittsburgh Medical Center (UPMC) (See: https://clinicaltrials...

In case you are interested https://marketwirenews.com/news-releases/hemispherx-biopharma-announces-first-patient-treated-in-phase-2-ovarian-cancer-clinical-trial-evaluating-ampligen-in-combination-with-pembrolizumab-and-cisplatin-8346632.html
👍️0
420man 420man 6 años hace
There's your RS... Let the shorting begin!!!
👍️0
cspratt15139 cspratt15139 6 años hace
Split coming
👍️0
420man 420man 6 años hace
.05
👍️0
Golden Cross Golden Cross 6 años hace
How low will it go before the RS is the question? I am staying out wish all GL
👍️0
whytestocks whytestocks 6 años hace
News: $HEB Hemispherx Biopharma Stockholders Approve Reverse Stock Split

OCALA, Fla., May 31, 2019 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE American: HEB), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency diseases, today announced that its stockholders voted in...

Read the whole news https://marketwirenews.com/news-releases/hemispherx-biopharma-stockholders-approve-reverse-stock-split-8277778.html
👍️0
cspratt15139 cspratt15139 6 años hace
When is the rs
👍️0
hebbeke47 hebbeke47 6 años hace
https://www.mrknewsroom.com/news-release/oncology/merck-provides-update-phase-3-keynote-119-study-keytruda-pembrolizumab-monothe
👍️0
carldfw carldfw 6 años hace
They have investors after the rs or people to buy in. They have been selling out with each pump. Hope they have a ringer in the fda. Or 10 years later the same pumps as 2008
👍️0
Golden Cross Golden Cross 6 años hace
HEB Daily Chart:

👍️0
whytestocks whytestocks 6 años hace
News: $HEB Hemispherx Links Stanford's ME/CFS Diagnostic to a Potential Path Forward for Ampligen Commercialization

OCALA, Fla., May 06, 2019 (GLOBE NEWSWIRE) -- Hemispherx Biopharma Inc., (NYSE American: HEB), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency diseases — and whose product portfolio includes Amp...

In case you are interested https://marketwirenews.com/news-releases/hemispherx-links-stanford-s-me-cfs-diagnostic-to-a-potential-path-forward-for-ampligen-commercialization-8123236.html
👍️0
Golden Cross Golden Cross 6 años hace
HEB on High Alert
👍️0
tknuncle tknuncle 6 años hace
WOW that's insane!!!! Thanks for sharing the actual numbers ;)
👍️0
420man 420man 6 años hace
So the warrant exercise price has been reduced to .15?! These guys are sucker punching retail! They would be delisted already if they traded on the the NAZ. JMO

The following table illustrates the dilution:

Offering price per share $0.15
Net tangible book value per share as of December 31, 2018 $(0.0875 )
Increase in net tangible book value per share after this offering $(0.0041)
Pro forma net tangible book value per share after this offering $(0.916 )

Dilution per share to the investor in this offering $0.0584
👍️0
pberger pberger 6 años hace
As I said several times, no value here, but pure CRAP.
👍️0
ClayTrader ClayTrader 6 años hace
* * $HEB Video Chart 05-02-2019 * *

Link to Video - click here to watch the technical chart video

👍️0
Golden Cross Golden Cross 6 años hace
sinking fast here
👍️0
nokomis nokomis 6 años hace
price of warrants reduced to .15 bearish
👍️0
pberger pberger 6 años hace
This pure CRAP is now below the "good news" from 2 days ago, such a TURD!!!
👍️0
Golden Cross Golden Cross 6 años hace
Nasty... Looking to buy back in on a big dip today
👍️0
ClayTrader ClayTrader 6 años hace
* * $HEB Video Chart 05-01-2019 * *

Link to Video - click here to watch the technical chart video

👍️0
Golden Cross Golden Cross 6 años hace
Nice news today!
👍️0
Zarate69 Zarate69 6 años hace
Dilution pure....
👍️0
tknuncle tknuncle 6 años hace
Where are all these shares coming from? It seems we have gone through all the OS after yesterday and this morning. We don't know what the float is but reading the OS at the OTC. So again were are all these shares coming from? The flippers have to be out now. Are the Shares being shorted by
the MM's? Again too new to trading to know what is going on with HEB..I would appreciate any input ;)
👍️0
aidytrader aidytrader 6 años hace
Where is the news? Thanks
👍️0
TommyBoyTrader9460 TommyBoyTrader9460 6 años hace
$heb..huge news out today..shorts scrambling premarket...
👍️0
JJGl JJGl 6 años hace
26s!!
👍️0

Su Consulta Reciente

AMEX
HEB
Hemispherx Biopharma
FX
EURUGX
Euro vs UGX
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2025 ADVFN PLC - Todos los derechos reservados